Viewing Study NCT06538012


Ignite Creation Date: 2025-12-26 @ 11:08 AM
Ignite Modification Date: 2026-02-25 @ 6:31 PM
Study NCT ID: NCT06538012
Status: RECRUITING
Last Update Posted: 2024-10-15
First Post: 2024-07-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Sponsor: Essen Biotech
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module